Evidence map›Paper›PMID 41800427›Full record

ArticleRegenerative engineering and translational medicine2025

A Pressure Regulator Platform for Applying Biomechanical Stimuli on Organ-on-A-Chip Systems with Physiological and Pathological Relevancy.

Carlos Ezio Garciamendez-Mijares, Francisco Aguilar Rojas, David S Rendon Ruiz, Xuan Mei, Pavel Hernandez, Begoña Sanchez Gonzalez, Jose Gerardo Marin Canchola, Victoria Abril Manjarrez Rivera, Ricardo Rodriguez, Francisco Lugo Mestre and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Regenerative engineering and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Carlos Ezio Garciamendez-MijaresDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Francisco Aguilar RojasDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
David S Rendon RuizDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Xuan MeiDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Pavel HernandezDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Begoña Sanchez GonzalezDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Jose Gerardo Marin CancholaDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Victoria Abril Manjarrez RiveraDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Ricardo RodriguezDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Francisco Lugo MestreDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Sushila MaharjanDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Shayan GholizadehDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Marie Denis Gerhard-HermanDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Yu Shrike ZhangDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.

Funding

High-throughput Imaging-integrated Vascular Model for Understanding Thromboembolism and Therapeutics ScreeningR01HL166522 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Junjie Yao, Y. Shrike Zhang · 2023 to 2026
$2.7M
Stretchable Hydrogel Bioinks-Enabled Microfluidic Bioprinting of Functional Small-Diameter Blood VesselsR01HL153857 · NHLBI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ZHAO, XUANHE · 2020 to 2024
$2.4M
High-Throughput Volumetric Photoacoustic Imaging of Living Vascularized OrganoidsR01EB028143 · NIBIB · DUKE UNIVERSITY · PI YAO, JUNJIE · 2019 to 2022
$2.0M
"Clinical Trials" on a Premature Vascular Aging-on-a-Chip ModelUH3TR003274 · NCATS · BRIGHAM AND WOMEN'S HOSPITAL · PI ZHANG, Y. SHRIKE · 2022 to 2024
$1.8M
A Bioprinted Volumetric Model of Vascularized GlioblastomaR01CA282451 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Kaisorn Lee Chaichana, Y. Shrike Zhang · 2023 to 2026
$1.7M
"Clinical Trials" on a Premature Vascular Aging-on-a-Chip ModelUG3TR003274 · NCATS · BRIGHAM AND WOMEN'S HOSPITAL · PI ZHANG, Y. SHRIKE · 2020 to 2021
$1.2M
Recapitulating Ductal Carcinoma on a Chip for Personalized Breast Cancer TherapyR00CA201603 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ZHANG, Y. SHRIKE · 2019 to 2021
$747k
Development of An Optoelectronically Active BioinkR21EB030257 · NIBIB · UNIVERSITY OF HOUSTON · PI YU, CUNJIANG · 2020 to 2020
$694k
Modeling Sex-Specific Cardiac Hypertrophy-on-a-ChipR21HL168656 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MAHARJAN, SUSHILA, ZHANG, Y. SHRIKE · 2024 to 2025
$492k
Developing Hybrids of Cardiac Tissue and Biodegradable Electronics Towards Heart Implants with On-line Monitoring and Stimulating FunctionsR21EB026175 · NIBIB · UNIVERSITY OF HOUSTON · PI YU, CUNJIANG · 2018 to 2019
$468k
NCATS NIH HHS UG3 TR003274NCATS NIH HHS UH3 TR003274NCI NIH HHS R00 CA201603NCI NIH HHS R01 CA282451NHLBI NIH HHS R01 HL153857NHLBI NIH HHS R01 HL166522NHLBI NIH HHS R21 HL168656NIBIB NIH HHS R01 EB028143NIBIB NIH HHS R21 EB026175NIBIB NIH HHS R21 EB030257
6 · The paper itself

Abstract

Purpose: The organ-on-a-chip (OOC) technology has transformed Methods: The PRP integrates hardware, electronics, and software to enable real-time generation of user-defined mechanical waveforms. Users can input patient-derived waveform profiles or select predefined waveforms, modifying frequency and amplitude to match physiological and pathological conditions. The PRP was tested on a blood vessel-on-a-chip model, evaluating its ability to replicate vascular biomechanics by applying controlled strain through vacuum-induced membrane deformation. Results: The PRP successfully reproduced patient-derived waveform profiles with high accuracy. The chip-agnostic design approach allowed seamless integration with multiple OOC configurations. Furthermore, this platform-maintained error levels below 1% for stabilized generic waveforms and achieved controlled vascular biomechanics in the OOC model, facilitating unidirectional alignment of vascular smooth muscle cells. Conclusion: The PRP provides a flexible and accessible platform for customizable and patient-derived biomechanical stimulation, enhancing the physiological relevance of

Indexed as

actuatorbiomechanical stimuliOrgan-on-a-chip (OOC)patho)physiological waveformspatient-specific

Identifiers

PMID41800427
PMCPMC12962595

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.